2023-2030 年葡萄膜炎全球市场

市场概览

葡萄膜炎的全球市场规模预计到 2022 年将达到 4.56 亿美元，到 2030 年将达到 8.37 亿美元，预测期内（2023-2030 年）的复合年增长率为 4.8%。

葡萄膜炎是一种眼睛炎症，会影响眼球内的中间组织层。 它主要发生在20至50岁的人群中。 葡萄膜炎是一个严重的问题，有时会导致视力丧失。

市场动态

推动全球葡萄膜炎市场发展的主要因素是由于青光眼和白内障等眼科疾病发病率的增加导致对葡萄膜炎的需求增加，提高认识活动，导致新药开发和新产品推出。这是技术的进步。

製药公司不断增加的产品线和不断提高的技术进步导致新药的开发预计将推动市场的增长。

葡萄膜炎市场的驱动因素包括技术进步不断加快、人口老龄化、研发投资激增、青光眼、白内障和 AMD 等眼科疾病的增加，以及对尖端技术和改进医疗基础设施的需求在新兴市场，它是由使用的新产品的改进驱动的。

葡萄膜炎药物广泛用于治疗目的。 这些设备越来越多地被采用，导致政府的举措和资金不断增加。 这些资金将帮助生产葡萄膜炎药物，例如眼药水、注射剂、药片和植入物。 随着患有这些眼病的患者数量不断增加，这些药物的市场正在全球范围内扩大。 此外，预计主要参与者提供的技术先进的产品也将在市场增长中发挥重要作用。

与这些葡萄膜炎治疗相关的各种新产品发布、研究和提高认识活动正在促进市场的增长。 例如，2022 年 11 月 1 日，Alimera Sciences 这家专注于患者维持视网膜健康和更好视力的製药公司宣布，其位于爱尔兰的欧洲子公司 Alimera Sciences Europe 将宣布获得 ILUVIEN（ fluocinolone acetonide 玻璃体内植入物），一种缓释眼内植入物，通过其分销合作伙伴 Medis 用于治疗非感染性葡萄膜炎。

高昂的治疗成本和高副作用风险预计会阻碍市场增长。

关于批准用于葡萄膜炎的药物的严格规章制度是阻碍葡萄膜炎市场增长的主要因素。 不同的要求，必须满足临床试验，导致这些药物的总体成本增加。 与这些治疗相关的高成本会阻碍增长。

此外，与这些药物副作用相关的高风险也限制了市场增长。 市场召回也是製约市场增长的主要因素。 由于植入物洩漏和并发症，已经有几次召回事件。

COVID-19 影响分析

疫情正在对全球金融预期、运营和危机应对策略产生负面影响。 COVID-19 的爆发严重影响了医疗保健行业。 由于 COVID，葡萄膜炎市场遭受了巨大损失。 主要製造商已经启动了各种研究和临床试验。 世界各地正在开展各种举措、产品发布、合作和合併，推动市场增长。 例如，2022 年 10 月 17 日，Kiora Pharmaceuticals, Inc. 公布了 KIO-100（原 PP-001）治疗非感染性葡萄膜炎（一种治疗眼部炎症性疾病）的 1 期试验结果，显示了其可能性。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

• 市场影响因素
  • 司机
    • 增加製药公司的产品线
    • 引领新药开发的技术进步
  • 约束因素
    • 高昂的治疗费用
    • 副作用风险高
  • 商机
  • 影响分析

第五章行业分析

• 波特的五力分析
• 供应链分析
• 定价分析

第 6 章 COVID-19 分析

• COVID-19 市场分析
  • COVID-19 之前的市场情景
  • COVID-19 的当前市场情景
  • COVID-19 后或未来情景
• COVID-19 期间的价格动态
• 供需范围
• 大流行期间与市场相关的政府举措
• 製造商的战略举措
• 总结

第 7 章葡萄膜炎的类型

• 前葡萄膜炎
• 中间葡萄膜炎
• 后葡萄膜炎
• 全葡萄膜炎

第8章药物

• 皮质类固醇
  • 倍他米松
  • 地塞米松
  • 可的松
  • 去炎松
  • 甲泼尼龙
• 抗风湿药
  • 霉酚酸酯
  • 环孢菌素
  • 硫唑嘌呤
  • 他克莫司
• Cycloprentic/散瞳
  • 托□卡胺
  • 环喷托酯
  • 去氧肾上腺素
  • 促生长素
  • 阿托品
• 免疫调节疗法
  • 硫唑嘌呤
  • 甲氨蝶呤
  • 霉酚酸酯
  • 环孢菌素
• 生物疗法
  • 英夫利昔单抗
  • 阿达木单抗
  • 达珠单抗
  • 干扰素-ALPHA
• 抗病毒剂
  • 阿昔洛韦
  • 伐昔洛韦
• 其他

第9章药物形式

• 眼药水
• 药丸
• 注射
• 植入

第 10 章最终用户

• 医院药房
• 零售药房
• 在线药店

第11章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第12章竞争格局

• 主要发展和战略
• 公司股票分析
• 产品基准
• 值得关注的主要公司名单

第13章公司简介

• 诺华公司
  • 公司简介
  • 产品组合和说明
  • 主要亮点
  • 财务摘要
  要

Market Overview

The global uveitis market size was valued at US$ 456 million in 2022 and is estimated to reach US$ 837 million by 2030, growing at a CAGR of 4.8% during the forecast period (2023-2030).

Uveitis is an eye inflammation, which affects the middle layer of the tissue in the eyewall. The majority of the alter lie in the population ages of 20 to 50 years. Uveitis can sometimes be a serious issue that can also lead to loss of vision.

Market Dynamics

The major factors driving the global uveitis market are the rising demand for uveitis owing to increasing incidences of ophthalmic disorders such as uveitis glaucoma and uveitis cataract, surging awareness initiatives, advancements in technologies leading to the development of new drugs and novel product launches.

The increasing product pipeline of pharma companies and rising technological advancements leading to the development of new drugs are expected to drive the market's growth.

The uveitis market is driven by rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of ophthalmic disorders such as uveitis glaucoma, uveitis cataract, AMD and improvements in novel products using the latest technology along with improvements in medical infrastructure in emerging markets.

The uveitis medications are used widely for treatment purpose. The adoption of these devices is increasing, leading to rising government initiatives and funds. These funds will help produce uveitis medication products such as eye drops, injections, pills or implants. The market for these medications is increasing worldwide due to the enhanced number of these ophthalmic disorders. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, research studies, and rising awareness initiatives related to these uveitis medications contribute to the market's growth. For instance, in November 1, 2022, Alimera Sciences, Inc., a pharmaceutical company focussed on patients with retinal health and maintaining longer and better vision, announced that its Ireland-based European subsidiary, Alimera Sciences Europe Limited, has been granted reimbursement for ILUVIEN (fluocinolone acetonide intravitreal implant) which is a sustained release intravitreal implant indicated for non-infectious uveitis, via Medis Pharmaceutical Company, its distribution partner.

High cost associated with the treatment and high risk of side effects are expected to hamper the market's growth.

Strict rules and regulations for the approval of medications utilized for uveitis is the major factor hindering the growth of the uveitis market. Various requirements, clinical trials must be fulfilled, leading to an increase in the overall cost of these medications. The high cost associated with these treatments is likely to hinder the growth.

High risk related to side effects of these medications is also limiting market's growth. Market recalls are also a leading factor restraining the growth of the market. Several recalls are taking place due to leakage or complications in implants.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The uveitis market has experienced huge losses due to COVID. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in October 17, 2022, Kiora Pharmaceuticals, Inc. announced its results from KIO-100 (formerly PP-001) Phase 1 study, showing its potential for non-infectious uveitis, an ophthalmic inflammatory disease treatment.

Segment Analysis

The anterior uveitis segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The anterior uveitis segment is the highest market holder in the global uveitis market. The global uveitis market is segmented based on disease type as anterior uveitis, intermediate uveitis, posterior uveitis and pan uveitis. The anterior uveitis segment is the largest market shareholder due to its increasing number of incidences globally, increasing technological advancements and novel product launches.

Anterior uveitis is the most common kind of uveitis which mostly affects the ciliary body and the inside of the front of eye (between the iris and the cornea). It is also also known as iritis. Anterior uveitis can be caused due to a trauma to the eye, like getting hit in the eye or having a foreign particle in the eye. It is also linked with common health problems including syphilis, rheumatoid arthritis, tuberculosis and viral (herpes simplex). Its symptoms include blurred vision, red or inflamed eye, small, irregular-shaped pupil and sensitivity to light.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drives the market's growth. For instance, in March 28, 2022, Bausch + Lomb, Bausch Health Companies' eye health business and Clearside Biomedical, Inc. a biopharmaceutical company transforming the therapies' delivery to the back of the eye via the suprachoroidal space (SCS) announced the commercial launch of XIPERE (triamcinolone acetonide injectable suspension) in U.S., the first therapy which got approval for suprachoroidal use by the U.S. Food and Drug Administration (FDA) for the macular edema associated with uveitis treatment.

Geographical Analysis

North America holds the largest market share in the global uveitis market.

North America dominates the global uveitis market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively moderate pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of uveitis medications in several ophthalmic conditions like uveitis glaucoma or uveitis cataract, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the uveitis market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in August 8, 2022, Clearside Biomedical, Inc., a biopharmaceutical company transforming the therapies' delivery to the back of the eye via the suprachoroidal space (SCS), announced about entering into a sale agreement with HealthCare Royalty Partners.

Competitive Landscape

The uveitis market is highly competitive with local and global companies' presence. Novartis Inc., AbbVie, Johnson & Johnson Services, Inc., Amgen, Alimera Sciences, Bausch & Lomb Incorporated., Kiora Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals, Inc., Clearside Biomedical and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in September 23, 2022, Alimera Sciences, Inc., a pharmaceutical company focussed on patients with retinal health and maintaining longer and better vision, announced its agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), to support and provide ILUVIEN (fluocinolone acetonide intravitreal implant) intravitreal implant for "A randomized clinical trial evaluating fluocinolone acetonide intravitreal implants or intravitreal faricimab injections vs due to Radiation Retinopathy visual acuity loss prevention observation.

Novartis AG

Overview: Novartis is engaged in discovering, developing, manufacturing, and selling a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Durezol: It is a topical corticosteroid which is indicated for pain and inflammation treatment linked with ocular surgery and endogenous anterior uveitis treatment.

Key Development: In June 17, 2022, Sandoz, a generic and biosimilar medicines provider, announced about application acceptance for high concentration formulation of its biosimilar Hyrimoz (adalimumab) by the European Medicines Agency (EMA) for regulatory review. The application covers all indications, including rheumatoid arthritis, uveitis, Crohn's disease, ulcerative colitis and plaque psoriasis

The global uveitis market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing product pipeline of pharma companies
    • 4.1.1.2. Rising advancements in technologies leading to the development of new drugs
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost associated with treatment
    • 4.1.2.2. High risk of side effects
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1 Porter's Five Forces Analysis
• 5.2 Supply Chain Analysis
• 5.3 Pricing Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Uveitis Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 7.1.2. Market Attractiveness Index, By Uveitis Type
• 7.2. Anterior Uveitis *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Intermediate Uveitis
• 7.4. Posterior Uveitis
• 7.5. Pan Uveitis

8. By Medications

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 8.1.2. Market Attractiveness Index, By Medications
• 8.2. Corticosteroids *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.2.3. Bethamethasone
  • 8.2.4. Dexamethasone
  • 8.2.5. Cortisone
  • 8.2.6. Triamcinolone
  • 8.2.7. Methylprednisolone
• 8.3. Anti-Rheumatic Drugs
  • 8.3.1. Mycophenolate
  • 8.3.2. Cyclosporine
  • 8.3.3. Azathioprine
  • 8.3.4. Tacrolimus
• 8.4. Cycloplegic-Mydriatic Drugs
  • 8.4.1. Tropicamide
  • 8.4.2. Cyclopentolate
  • 8.4.3. Phenylephrine
  • 8.4.4. Homatropine
  • 8.4.5. Atropine
• 8.5. Immunomodulatory Therapy
  • 8.5.1. Azathioprine
  • 8.5.2. Methotrexate
  • 8.5.3. Mycophenolate Mofetil
  • 8.5.4. Cyclosporine
• 8.6. Biological Therapy
  • 8.6.1. Infliximab
  • 8.6.2. Adalimumab
  • 8.6.3. Daclizumab
  • 8.6.4. Interferon-Alfa
• 8.7. Anti-Viral Drugs
  • 8.7.1. Aciclovir
  • 8.7.2. Valaciclovir
• 8.8. Others

9. By Medication Form

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 9.1.2. Market Attractiveness Index, By Medication Form
• 9.2. Eye Drops *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Pills
• 9.4. Injections
• 9.5. Implants

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospital Pharmacies *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Key Developments and Strategies
• 12.2. Company Share Analysis
• 12.3. Products Benchmarking
• 12.4. List of Key Companies to Watch

13. Company Profiles

• 13.1. Novartis AG *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Key Highlights
  • 13.1.4. Financial Overview
• 13.2. AbbVie
• 13.3. Johnson & Johnson Services, Inc.
• 13.4. Amgen
• 13.5. Alimera Sciences
• 13.6. Bausch & Lomb Incorporated.
• 13.7. Kiora Pharmaceuticals, Inc.
• 13.8. Santen Pharmaceutical Co., Ltd.
• 13.9. EyePoint Pharmaceuticals, Inc.
• 13.10. Clearside Biomedical

LIST NOT EXHAUSTIVE

14. Global Uveitis Market - DataM

• 14.1. Appendix
• 14.2. About Us and Medications
• 14.3. Contact Us